Lumakras Drug Clinical Insight & Sales Forecast 2026 Report Highlights:
- NSCLC Targeting Lumakras Market Opportunity (US$ Million)
- Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
- Pharmacokinetics of Lumakras (Sotorasib)
- Dosage, Patent & Price Analysis
- Lumakras Ongoing Clinical Trials
- Global KRAS Protein Inhibitors Clinical Trials
The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management of cancer. Despite huge advancements in the field of cancer therapeutics, there has been no permanent cure of cancer till now. However, the advancement in the field of science and technology has led to the identification of potential targets which can be utilized in drug development process.
The identification of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene as well as its potential role in the pathogenesis and proliferation of cancer has shown to be boon in cancer therapeutics. The extensive research and development by the researchers has led to the discovery of novel KRAS inhibitors which are used in the management of rare ALK positive cancers. Till now, only one KRAS inhibitor has been approved for the management of non-small cell lung cancer.
Lumakras (Sotorasib) is first KRAS inhibitor developed by Amgen and was approved by FDA in May, 2021. Lumakras is a once-daily oral prescription medicine used to treat adults living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. The approval of Lumakras represents as one of the major revolution in the field of cancer treatment.
Owing to their favorable characteristics in management of NSCLC as well its high specificity and efficacy, it is expected that Lumakras market will witness high growth rates. As per report findings, it is expected that Lumakras market is expected to surpass US$ 1.5 Billion by 2026. This is due to the ability of Lumakras in overcoming the limitations of already conventional cancer therapies. Moreover, the drug Lumakras is not associated with side effects in comparison to conventional cancer treatments and also improved the survival rates in patients.
Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years. However, increasing initiatives by government and the pharmaceutical companies for the development of favorable reimbursement policies will help in lowering the cost of the therapy, thus reducing financial toxicity on patients.
The global Lumakras market will follow trajectory path during the forecast period owing to the single product approval. In addition to this, researchers are also evaluating the role of Lumakras in other solid tumors as well in combination of other immunotherapeutic drugs, which will drive the growth of market. North America particularly US is expected to dominate the global Lumakras market for next few years owing to increase in prevalence of non-small cell lung cancer and the presence of large pharmaceutical companies which actively indulge in research and development activities.
The report global Lumakras market contains information on the price, dosage and expected sales of the drug in different regions. In addition to this, it also provides information on the safety, efficacy, pharmacokinetics, and pharmacovigilance profile of Lumakras. The report also provides insights on the recent clinical trials undergoing with the drug and predict the future market of the drug at a global level.
Table of Contents
1. Lumakras (Sotorasib) - First Approved KRAS Inhibitor Drug
1.1 Market Overview
1.2 Future Opportunity
2. Lumakras - Mechanism of Action
3. Lumakras - Structure, Description & Pharmacokinetics
3.1 Chemistry & Physical Properties
3.2 Pharmacokinetics
4. Role of Lumakras in NSCLC
5. Role in Lumakras in Solid Tumors
6. Lumakras - Commercial Aspects
6.1 Overview & Patent Insight
6.2 Dosage & Price Analysis
7. Lumakras - Supplementary Information
7.1 Adverse Drug Reactions
7.2 Drug Interaction
7.2.1 Effects of Other Drugs on Lumakras
7.2.2 Effects of Lumakras on Other Drugs
8. Lumakras Ongoing Clinical Trials
8.1 Global KRAS Protein Inhibitors Clinical Trials
8.2 Global Lumakras Clinical Trials
9. Clinical Development Trends by Regions
9.1 US
9.2 Rest of World
10. Companies Involved in Development of KRAS Inhibitors
10.1 Amgen
10.2 Boehringer Ingelheim
10.3 Codiak Biosciences
10.4 Cotinga Pharmaceuticals
10.5 Eli Lilly
10.6 Gilead
10.7 Johnson & Johnson
10.8 Mirati Therapeutics
10.9 Merck
10.10 Moderna
10.11 Oblique Therapeutics
10.12 Revolution Medicines
10.13 Silenseed
Table of Figures
Figure 1-1: Global - Frequency of KRAS G12C Mutation by Cancer Type (%), 2021 & 2026
Figure 1-2: Global - KRAS Mutation by Type (%), 2020
Figure 1-3: Global - Estimated KRAS Mutated NSCLC Population for KRAS Inhibitors, 2021 & 2026
Figure 1-4: Global - NSCLC Targeting Lumakras Market Opportunity by 5% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-5: Global - NSCLC Targeting Lumakras Market Opportunity by 10% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-6: Global - NSCLC Targeting Lumakras Market Opportunity by 15% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-7: Global - NSCLC Targeting Lumakras Market Opportunity by 20% Targeted Population (US$ Billion), 2021 - 2026
Figure 1-8: Global - NSCLC Targeting Lumakras Market Opportunity by 25% Targeted Population (US$ Billion), 2021 - 2026
Figure 1-9: Global - Estimated KRAS G12C Mutated Colorectal Cancer Population for KRAS Inhibitors, 2021 & 2026
Figure 1-10: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 5% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-11: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 10% of Targeted Population (US$ Billion), 2021 - 2026
Figure 1-12: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 15% of Targeted Population (US$ Million), 2021 - 2026
Figure 1-13: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 20% Targeted Population (US$ Billion), 2021 - 2026
Figure 1-14: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 25% Targeted Population (US$ Billion), 2021 - 2026
Figure 2-1: General Mechanism of KRAS Inhibitors against Cancer
Figure 2-2: Targeting Approaches of KRAS Inhibitors
Figure 2-3: Mechanism of Lumakras - Direct Targeting of Mutant KRAS
Figure 3-1: Structure of Lumakras
Figure 4-1: Global - Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020
Figure 4-2: Global - Lung Cancer Incidence by Type (%), 2020
Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer
Figure 5-1: Global - Frequency of Overall KRAS Mutation & KRAS G12C Mutation (%)
Figure 6-1: Lumakras - FDA Approval & Patent Expiration Year
Figure 6-2: Lumakras - Price for 240 Tablet Supply & Price Per Unit of 120mg Tablet (US$), July’2021
Figure 6-3: Lumakras - Monthly & Annual Treatment Cost (US$), July’2021
Figure 6-4: Lumakras - Recommended Initial & Reduced Dose (mg/day)
Figure 7-1: Lumakras - List of Adverse Events
Figure 8-1: Global - KRAS Protein Inhibitors Clinical Trials by Phase, 2020 -2026
Figure 8-2: Global - KRAS Protein Inhibitors Clinical Trials by Country, 2020 -2026
Figure 8-3: Global - KRAS Protein Inhibitors Clinical Trials by Company, 2020 -2026
Figure 8-4: Global - KRAS Protein Inhibitors Clinical Trials by Indication, 2020 -2026
Figure 8-5: Global - KRAS Protein Inhibitors Clinical Trials by Patient Segment, 2020 -2026
Figure 8-6: Global - Number of KRAS G12C Inhibitors in Clinical Trial by Phase, July 2021
Figure 8-7: Global - KRAS G12C Inhibitors in Clinical Trial by Phase (%), July 2021
Figure 8-8: Codebreak 200 Trial - Study Initiation & Expected Completion Year
Figure 8-9: Codebreak 105 Trial - Study Initiation & Expected Completion Year
Figure 8-10: Codebreak 101 Trial - Study Initiation & Expected Completion Year
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Boehringer Ingelheim
- Codiak Biosciences
- Cotinga Pharmaceuticals
- Eli Lilly
- Gilead
- Johnson & Johnson
- Mirati Therapeutics
- Merck
- Moderna
- Oblique Therapeutics
- Revolution Medicines
- Silenseed
